BioDuro-Sundia, a leading contract research, development and manufacturing organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as Chief Executive Officer. Dr. Spura brings more than two decades of experience in the life sciences and biotechnology industries, with a proven track record of driving growth and innovation in global markets.
Dr. Spura joins BioDuro-Sundia from Crown Bioscience, where he served as CEO for nearly five years, guiding the company through significant growth and strategic development. Throughout his career, Dr. Spura has held leadership positions at several well-known organizations such as Thermo Fisher Scientific, WuXi NEXTCODE, CareDx and Ion Torrent. He also holds various advisory roles, including as Chairman of the Board of SeromYx Systems and as a Life Sciences Investment Advisor at K2X Technology and Life Science.
Early in his career, Dr. Spura helped grow two startups: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied biochemistry in Germany and received his Ph.D. in molecular biology from Brown University in the United States.
Also Read: Trailhead Biosystems Announces Joshua Snow as CCO
“ I am honored to join BioDuro-Sundia and lead this talented team as we embark on the next phase of growth,” said Dr. Spura. “ With our unique, fully integrated CRDMO platform spanning chemistry, biology, drug metabolism and pharmacokinetics, drug substance and drug product, from discovery to commercial manufacturing, I am confident we will empower more partners to bring better treatments to patients around the world faster.”
Gary Chu, Chairman of the Company’s Executive Committee, Operations, added: “ Dr. Spura’s extensive global experience and visionary leadership are critical to driving BioDuro-Sundia’s accelerated growth. We are excited and confident that under his leadership, we will continue to innovate and deliver integrated solutions that meet the growing needs of our customers around the world and the broader healthcare community.”
BioDuro-Sundia, an Advent International portfolio company, is a CRDMO with a proven track record of 28 years. Headquartered in Irvine, California, USA, the company has a global presence with seven sites in the US and China, and employs over 2,000 employees. Specializing in the discovery, development, scale-up and manufacturing of small and large molecules, we offer fully integrated services from early drug discovery through chemistry, biology, drug metabolism and pharmacokinetics, drug substance and drug product to commercial manufacturing.
SOURCE: Businesswire